Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
NEO

NeoGenomics Inc

NEO

18.34USD+0.40 (+2.23%)Market Closed
Watchlist

Market Summary

USD18.34+0.40
Market Closed
2.23%

NEO Alerts

  • Big jump in Earnings (Y/Y)
  • Losses in recent quarter

NEO Stock Price

View Fullscreen

NEO RSI Chart

NEO Valuation

Market Cap

2.3B

Price/Earnings (Trailing)

-24.23

Price/Sales (Trailing)

4.06

EV/EBITDA

-27.61

Price/Free Cashflow

-47.01

NEO Price/Sales (Trailing)

NEO Profitability

EBT Margin

-18.67%

Return on Equity

-10.17%

Return on Assets

-5.74%

Free Cashflow Yield

-2.13%

NEO Fundamentals

NEO Revenue

Revenue (TTM)

574.8M

Revenue Y/Y

17.99%

Revenue Q/Q

3.43%

NEO Earnings

Earnings (TTM)

-96.3M

Earnings Y/Y

49.76%

Earnings Q/Q

23.9%

Price Action

Last 7 days

-3.5%

Last 30 days

15.9%

Last 90 days

34.9%

Trailing 12 Months

52.0%

How does NEO drawdown profile look like?

NEO Financial Health

Current Ratio

6.32

NEO Investor Care

Shares Dilution (1Y)

0.55%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023529.8M551.6M574.8M0
2022486.0M489.3M496.8M509.7M
2021454.0M488.7M484.6M484.3M
2020419.3M404.5M425.3M444.4M
2019308.9M342.9M378.4M408.8M
2018246.2M251.7M261.7M276.7M
2017241.8M240.9M239.3M240.3M
2016136.5M175.2M210.9M244.1M
201591.9M95.6M97.5M99.8M
201469.0M74.1M80.4M87.1M
201360.4M60.4M63.0M66.5M
201249.8M55.0M57.9M59.9M
201136.6M38.9M41.2M43.5M
201000034.4M

Latest Insider Trading transactions for NEO

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 01, 2023
stone warren
sold (taxes)
-
-
-5,431
president, clinical services
Nov 17, 2023
olivo alicia c
sold
-49,082
18.39
-2,669
general counsel
Sep 30, 2023
olivo alicia c
sold (taxes)
-
-
-14.00
general counsel
Sep 01, 2023
olivo alicia c
sold (taxes)
-
-
-1,666
general counsel
Aug 01, 2023
olivo alicia c
sold (taxes)
-
-
-14.00
general counsel
Jun 01, 2023
sikri vishal
sold (taxes)
-
-
-21,406
president advanced diagnostics
May 22, 2023
tetrault lynn a.
acquired
17,481
11.6
1,507
-
May 01, 2023
olivo alicia c
sold (taxes)
-
-
-662
general counsel
Apr 01, 2023
kulkarni shashikant
sold (taxes)
-
-
-3,759
chief scientific officer
Mar 02, 2023
dieter cynthia j
sold (taxes)
-
-
-117
chief accounting officer

1–10 of 50

Which funds bought or sold NEO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Dec 06, 2023
CITIGROUP INC
reduced
-44.39
-915,093
678,087
-%
Dec 06, 2023
Raleigh Capital Management Inc.
unchanged
-
-720
2,349
-%
Dec 04, 2023
TUCKER ASSET MANAGEMENT LLC
unchanged
-
-754
2,460
-%
Nov 24, 2023
DEUTSCHE BANK AG\
added
6.95
-275,374
1,242,950
-%
Nov 22, 2023
KBC Group NV
unchanged
-
-
162,000
-%
Nov 22, 2023
Public Sector Pension Investment Board
reduced
-30.37
-1,699,570
1,939,510
0.01%
Nov 22, 2023
Graham Capital Management, L.P.
reduced
-33.02
-453,115
476,711
0.01%
Nov 21, 2023
Walleye Capital LLC
new
-
331,018
331,018
-%
Nov 21, 2023
COMERICA BANK
new
-
790,053
790,053
-%
Nov 21, 2023
COMERICA BANK
sold off
-100
-
-
-%

1–10 of 36

Latest Funds Activity

Are funds buying NEO calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own NEO
No. of Funds

Schedule 13G FIlings of NeoGenomics Inc

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 10, 2023
artisan partners limited partnership
0.0%
10
SC 13G/A
Feb 09, 2023
vanguard group inc
10.83%
13,674,745
SC 13G/A
Feb 09, 2023
brown advisory inc
5%
6,337,008
SC 13G
Feb 06, 2023
wellington management group llp
0.00%
0
SC 13G/A
Jan 23, 2023
blackrock inc.
17.4%
21,932,623
SC 13G/A
Feb 04, 2022
wellington management group llp
8.99%
11,069,283
SC 13G
Feb 04, 2022
artisan partners limited partnership
6.3%
7,732,355
SC 13G
Jan 27, 2022
blackrock inc.
15.7%
19,328,254
SC 13G/A
Jan 26, 2022
blackrock inc.
15.7%
19,328,254
SC 13G
Feb 10, 2021
vanguard group inc
10.06%
11,167,578
SC 13G/A

Recent SEC filings of NeoGenomics Inc

View All Filings
Date Filed Form Type Document
Dec 05, 2023
4
Insider Trading
Nov 20, 2023
4
Insider Trading
Nov 17, 2023
144
Notice of Insider Sale Intent
Nov 06, 2023
8-K
Current Report
Nov 06, 2023
10-Q
Quarterly Report
Oct 03, 2023
4
Insider Trading
Sep 05, 2023
4
Insider Trading

NEO Fair Value

Loading...

Peers (Alternatives to NeoGenomics Inc)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
160.7B
29.6B
10.51% -19.98%
27.16
5.44
-5.39% -12.54%
44.1B
3.6B
24.23% 23.99%
53.65
12.3
7.43% 22.86%
37.3B
7.0B
16.28% -18.61%
32.89
5.33
5.03% -14.68%
15.2B
9.3B
1.84% -9.68%
19.95
1.64
-9.69% -38.22%
11.7B
2.4B
2.99% 40.82%
-41.48
4.86
19.99% 60.62%
MID-CAP
10.5B
4.2B
16.20% -2.67%
22.08
2.49
11.49% 8.84%
8.7B
1.8B
2.84% 34.94%
31.81
4.88
29.62% 20.49%
6.9B
988.7M
40.66% 50.03%
-13.86
7
27.41% 8.51%
3.9B
919.1M
17.21% 17.06%
-147.97
4.28
73.02% -172.93%
3.0B
535.8M
8.75% -45.64%
-7.02
5.66
24.38% 26.34%
SMALL-CAP
531.2M
297.1M
54.98% -22.82%
-5.87
1.79
-6.74% -21.60%
71.5M
21.4M
-81.47% -93.49%
-0.62
3.34
-8.80% -39.66%
31.2M
9.2M
-11.33% -33.68%
-1.76
3.4
16.43% 48.38%
12.0M
13.4M
-4.35% -39.31%
-1.21
0.9
-26.43% -20.54%
120.4K
-
-82.76% -93.43%
0
0.76
-57.78% -93.13%

NeoGenomics Inc News

Latest updates
MarketBeat09 Dec 202310:14 am16 hours ago
Marketscreener.com06 Dec 202302:13 pm3 days ago
Stocks Register02 Dec 202304:00 pm7 days ago
Defense World01 Dec 202309:53 am8 days ago
InvestorsObserver27 Nov 202306:13 pm12 days ago
GuruFocus.com20 Nov 202308:00 am19 days ago
Seeking Alpha08 Nov 202308:00 am31 days ago
Yahoo Finance06 Nov 202308:00 am33 days ago
Yahoo Finance01 Nov 202307:00 am38 days ago
Yahoo Finance30 Oct 202307:00 am40 days ago
Yahoo Finance24 Oct 202307:00 am46 days ago
Yahoo Finance24 Oct 202307:00 am46 days ago
Yahoo Finance13 Oct 202307:00 am57 days ago
Yahoo Finance05 Oct 202307:00 am2 months ago

Financials for NeoGenomics Inc

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue3.4%151,954,000146,917,000137,220,000138,705,000128,782,000125,072,000117,169,000125,732,000121,340,000121,724,000115,533,000125,997,000125,444,00086,977,000106,030,000106,868,000104,672,000101,713,00095,577,00076,475,00069,097,000
Gross Profit4.0%62,311,00059,891,00054,814,00056,825,00048,893,00043,946,00038,232,00045,257,00047,239,00052,990,00041,574,00057,453,00054,065,00028,006,00046,369,00049,923,00050,832,00048,966,00047,115,00037,111,00032,321,000
Operating Expenses-3.7%86,506,00089,785,00089,887,00083,208,00088,403,00083,648,00090,260,00086,824,00086,952,00075,357,00056,681,00051,914,00049,396,00046,913,00051,662,00047,602,00047,173,00044,488,00044,567,00034,289,50028,401,000
  S&GA Expenses-6.8%17,610,00018,901,00016,259,00017,142,00016,809,00017,071,00016,299,00015,917,00015,704,00017,224,00013,749,00013,105,00011,304,00010,195,00013,258,00012,302,00011,508,00012,324,00011,216,0008,047,0006,900,000
  R&D Expenses-29.6%5,285,0007,502,0007,395,0006,675,0007,312,0008,626,0007,713,0008,513,0007,409,0003,495,0002,456,0002,100,0001,964,0002,105,0002,060,0002,080,0002,611,0002,587,0001,209,000526,000446,000
EBITDA Margin20.8%-0.13-0.16-0.19-0.24-0.28-0.25-0.020.040.150.200.010.040.010.010.06------
Interest Expenses-12.5%-2,840,000-2,524,0001,467,000441,000139,000926,000-1,301,0001,707,0001,296,000902,0001,177,0002,194,0002,458,0001,548,000819,000380,000203,0001,304,0001,826,0001,464,0001,873,000
Income Taxes-27.1%-2,935,000-2,309,000-2,925,000-2,837,000-2,772,000-5,730,000-3,753,000-2,445,000-2,822,000-2,437,000976,000-7,850,000-335,000-11,132,0001,089,000-3,861,0001,348,000175,000-2,023,0001,049,00054,000
Earnings Before Taxes19.5%-21,451,000-26,640,000-33,720,000-25,524,000-39,624,000-41,033,000-53,161,000-44,203,500-23,170,00073,436,000-21,138,0007,567,0002,222,000-17,956,000-5,889,0002,435,0003,491,0002,166,000-4,447,0001,402,0002,077,000
EBT Margin17.9%-0.19-0.23-0.26-0.31-0.36-0.33-0.10-0.030.080.13-0.06-0.03-0.05-0.040.01------
Net Income23.9%-18,516,000-24,331,000-30,795,000-22,687,000-36,852,000-35,303,000-49,408,000-41,758,500-20,348,00075,873,000-22,114,00015,417,0002,557,000-6,824,000-6,978,0006,296,0002,143,0001,991,000-2,424,000353,0002,023,000
Net Income Margin19.4%-0.17-0.21-0.24-0.28-0.33-0.30-0.07-0.020.100.15-0.020.01-0.01-0.010.01------
Free Cashflow-8.1%-9,771,000-9,042,000-22,619,000-8,219,000-24,116,000-27,290,000-37,259,000-31,763,000-22,744,000-22,737,000-13,621,000-5,520,000-7,331,000-3,144,000-11,641,000------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-1.0%1,6781,6951,7091,7401,7561,7921,8301,8701,9061,8961,494988959945732710711697533505455
  Current Assets0.4%587585585605603622651682710722943449422419215291292276116104194
    Cash Equivalents5.9%30628927626326628430631734136961222923329586.0017317916713.0010.00118
  Inventory-3.6%24.0025.0024.0024.0024.0022.0024.0023.0022.0021.0021.0030.0021.0022.0020.0014.0013.009.0010.009.007.00
  Net PPE-5.6%95.0010010310210711110910910711294.0086.0085.0084.0083.0064.0062.0059.0061.0061.0041.00
  Goodwill0%52352352352352352752752752626745.00211211211211199199196196198147
Liabilities-1.1%731739735742743749755762769748651294293291227202214207209185152
  Current Liabilities-2.0%93.0095.0087.0090.0085.0083.0082.0087.0093.0099.0068.0073.0065.0062.0068.0064.0069.0059.0073.0061.0047.00
Shareholder's Equity-0.9%9479569749981,0131,0441,0751,1081,1371,148844694666654505507497490324320304
  Retained Earnings-8.6%-232-214-189-159-136-99.55-64.24-14.8427.0047.00-28.60-7.18-22.60-25.16-18.33-11.36-17.65-51.69-53.68-19.36-51.56
  Additional Paid-In Capital0.8%1,1821,1731,1671,1611,1541,1471,1421,1241,1111,101872701689679526520517543379340354
Accumulated Depreciation5.0%15514713913212512311611011210599.0093.0086.0080.0074.0069.0064.0059.0055.0050.0049.00
Shares Outstanding0.1%12712712712712712412412412311811611211010810410510498.0095.0094.0087.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-255.1%-5,497-1,548-12,692-3,685-16,272-16,996-29,040-19,776-7,767-1,3902,2105,9855261,882-6,9333,35918,634-4,7216,09715,4538,381
  Share Based Compensation25.9%7,1805,7054,7584,6634,2803,62612,10310,0625,2374,5062,6532,6762,7152,6352,1862,2733,2752,3132,1391,8071,191
Cashflow From Investing39.3%20,82114,94923,742-1,063-4,198-6,27412,052-9,583-14,686-453,410-154,688-28,854-70,716-18,163-41,708-6,076-7,316-3,042-3,196-128,596-2,148
Cashflow From Financing2776.6%1,84164.001,3791,8022,9591,0116,0572,460-6,720204,610524,9358,2654,115222,600617-3,158137162,0044834,547102,785

NEO Income Statement

2023-09-30
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Total net revenue$ 151,954,000$ 128,782,000$ 436,091,000$ 371,023,000
COST OF REVENUE89,643,00079,889,000259,075,000239,952,000
GROSS PROFIT62,311,00048,893,000177,016,000131,071,000
Operating expenses:    
General and administrative61,486,00064,282,000183,343,000188,481,000
Research and development5,285,0007,312,00020,182,00023,651,000
Sales and marketing17,610,00016,809,00052,770,00050,179,000
Restructuring charges2,125,00009,883,0000
Total operating expenses86,506,00088,403,000266,178,000262,311,000
LOSS FROM OPERATIONS(24,195,000)(39,510,000)(89,162,000)(131,240,000)
Interest (income) expense, net(2,840,000)139,000(6,831,000)2,366,000
Other expense (income), net96,000(25,000)(520,000)212,000
Loss before taxes(21,451,000)(39,624,000)(81,811,000)(133,818,000)
Income tax benefit(2,935,000)(2,772,000)(8,169,000)(12,255,000)
NET LOSS$ (18,516,000)$ (36,852,000)$ (73,642,000)$ (121,563,000)
NET LOSS PER SHARE    
Basic (in dollars per share)$ (0.15)$ (0.30)$ (0.59)$ (0.98)
Diluted (in dollars per share)$ (0.15)$ (0.30)$ (0.59)$ (0.98)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING    
Basic (in shares)125,687124,425125,358124,055
Diluted (in shares)125,687124,425125,358124,055
Clinical Services    
Total net revenue$ 127,553,000$ 106,162,000$ 365,578,000$ 310,588,000
COST OF REVENUE73,994,00065,261,000213,032,000197,563,000
GROSS PROFIT53,559,00040,901,000152,546,000113,025,000
Advanced Diagnostics    
Total net revenue24,401,00022,620,00070,513,00060,435,000
COST OF REVENUE15,649,00014,628,00046,043,00042,389,000
GROSS PROFIT$ 8,752,000$ 7,992,000$ 24,470,000$ 18,046,000

NEO Balance Sheet

2023-09-30
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 306,239$ 263,180
Marketable securities, at fair value96,025174,809
Accounts receivable, net132,640119,711
Inventories24,05324,277
Prepaid assets18,67615,237
Other current assets9,3178,077
Total current assets586,950605,291
Property and equipment (net of accumulated depreciation of $154,840 and $131,930, respectively)94,517102,499
Operating lease right-of-use assets87,13196,109
Intangible assets, net381,910408,260
Goodwill522,766522,766
Other assets4,9675,109
Total non-current assets1,091,2911,134,743
Total assets1,678,2411,740,034
Current liabilities  
Accounts payable16,81920,510
Accrued compensation47,59440,141
Accrued expenses and other liabilities18,67915,070
Current portion of equipment financing obligations470
Current portion of operating lease liabilities6,2136,584
Contract liabilities3,6177,557
Total current liabilities92,92689,932
Long-term liabilities  
Convertible senior notes, net537,475535,322
Operating lease liabilities62,00768,952
Deferred income tax liabilities, net25,37034,750
Other long-term liabilities13,03513,055
Total long-term liabilities637,887652,079
Total liabilities730,813742,011
Commitments and contingencies (Note 11)
Stockholders’ equity  
Common stock, $0.001 par value, (250,000,000 shares authorized; 127,261,476 and 126,913,992 shares issued and outstanding, respectively)127127
Additional paid-in capital1,181,8761,160,882
Accumulated other comprehensive loss(1,846)(3,899)
Accumulated deficit(232,729)(159,087)
Total stockholders’ equity947,428998,023
Total liabilities and stockholders’ equity$ 1,678,241$ 1,740,034
NEO
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
 CEO
 WEBSITEwww.neogenomics.com
 EMPLOYEES2100

NeoGenomics Inc Frequently Asked Questions


What is the ticker symbol for NeoGenomics Inc? What does NEO stand for in stocks?

NEO is the stock ticker symbol of NeoGenomics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of NeoGenomics Inc (NEO)?

As of Fri Dec 08 2023, market cap of NeoGenomics Inc is 2.33 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NEO stock?

You can check NEO's fair value in chart. The fair value of NeoGenomics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of NeoGenomics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NEO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is NeoGenomics Inc a good stock to buy?

The fair value guage provides a quick view whether NEO is over valued or under valued. Whether NeoGenomics Inc is cheap or expensive depends on the assumptions which impact NeoGenomics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NEO.

What is NeoGenomics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 08 2023, NEO's PE ratio (Price to Earnings) is -24.23 and Price to Sales (PS) ratio is 4.06. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NEO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on NeoGenomics Inc's stock?

In the past 10 years, NeoGenomics Inc has provided 0.175 (multiply by 100 for percentage) rate of return.